News

Rapid MDx on infections
Enlarge image

BusinessUKFinlandFranceIreland

Rapid MDx on infections

03.09.2012 - EU-funded researchers will use a €6m grant to develop cost-effective molecular diagnostics (MDx) tools for the rapid diagnosis of infections.

The aim is to come up with a test that would reduce the diagnosis time of respiratory tract infections from days to hours, so that the appropriate treatments can be administered as early as possible, giving patients the best possible chance of a swift recovery. These diagnostic products will be based on a novel "sample-in, result-out" technology platform.
The project, titled RID-RTI ('Rapid Identification of Respiratory Tract Infections'), brings together researchers from small and medium-sized enterprises (SMEs), universities and hospitals. The Molecular Diagnostics Research Group at the National University of Ireland, Galway; French diagnostics firm Genewave;  Finnish biotech company Mobidiag; Assistance Publique Hopitaux de Paris; and University College London are part of the consortium. They receive a €6m boost of funding from the EU's Seventh Framework Programme (FP7).
Respiratory tract infections, such as pneumonia, are amongst the top four major causes of morbidity and mortality worldwide. „Speed and accuracy are key to appropriate therapy and survival of the patient. The ultimate objective is to develop new cost effective, user-friendly products that will be routinely used in hospitals“, stated Thomas Barry from the Molecular Diagnostics Research Group at NUI Galway in Ireland. „This could replace time-consuming and labour-intensive methods so that a diagnosis can be achieved within a couple of hours, rather than days or weeks.“

BusinessGermanyFrance

15.04.2014 German flavour and scent specialist Symrise has announced its plans to acquire French pet-food ingredients maker Diana Group for €1.3bn.

BioeconomySpain

14.04.2014 Spanish Neol Biosolutions and the Center for Second Generation Biofuels are starting a partnership to scale-up Neol's waste-to-oil technology.

EvidenceUKSwitzerland

11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.

BusinessSwitzerlandSpain

09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.

Status ReportSwitzerland

08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.

NanobiotechnologyItaly

07.04.2014 Scientists from the University of Udine have designed, produced and tested a prototype for a "DNA origami" nanorobot that can potentially deliver biological activators in-vivo.

EpidemicEUFranceGermanyItaly

02.04.2014 As the Ebola epidemic in Guinea worsens, Europe is deploying the specialists of EMLab to provide diagnostics at the focus of the outbreak.

BioeconomyFranceEU

01.04.2014 The European Commission has approved a French state package aid worth €43m for green chemistry project IEED.

MonitoringEU

27.03.2014 In Europe, bacterial resistance to prevalent antimicrobials is common, while multi-resistance remains low, EFSA and ECDC now report.

FinancingFrance

25.03.2014 Immunotherapy developer Transgene SA has successfully raised a total of €65.5m via a two-step capital increase – including a rights issue and a private placement.

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS (CH)0.23 CHF53.3%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%
  • CO.DON (D)3.40 EUR9.7%

FLOP

  • WILEX (D)0.88 EUR-15.4%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • FLAMEL TECHNOLOGIES (F)11.01 USD-13.5%

TOP

  • CO.DON (D)3.40 EUR91.0%
  • WILEX (D)0.88 EUR51.7%
  • BIOTECH PHARMACON (N)17.50 NOK50.9%

FLOP

  • CYTOS (CH)0.23 CHF-92.0%
  • BIONOR PHARMA (N)2.11 NOK-47.9%
  • GW PHARMACEUTICALS (UK)219.50 GBP-46.5%

TOP

  • SILENCE THERAPEUTICS (UK)255.00 GBP5900.0%
  • IXICO (UK)69.50 GBP776.4%
  • PLETHORA (UK)11.00 GBP609.7%

FLOP

  • CYTOS (CH)0.23 CHF-94.7%
  • EVOCUTIS (UK)0.22 GBP-92.9%
  • AGENNIX (D)0.04 EUR-78.9%

No liability assumed, Date: 15.04.2014